Thermo Fisher Scientific Inc. (TMO) Stock Analysis
Latest ClaritX AI analysis ·
Thermo Fisher Scientific Inc. is a global leader in scientific services, providing a comprehensive range of offerings that include life sciences solutions, advanced analytical instruments, specialized diagnostic products, and an extensive portfolio of laboratory supplies and biopharmaceutical services. The company's reach extends across North America, Europe, Asia-Pacific, and other international markets. Its Life Sciences Solutions division furnishes researchers with essential reagents, state-of-the-art instruments, and consumables vital for biological and medical exploration, the development and manufacturing of therapeutics and vaccines, and the detection of infections and various disease
| Metric | Value |
|---|---|
| Price | $654.80 |
| Market cap | $242.1B |
| Sector | Healthcare |
| Industry | Medical - Diagnostics & Research |
| ClaritX AI score | 87/100 |
| Price/Book | 4.61 |
| Dividend yield | 0.28% |
| Beta | 0.85 |
AI verdict
Thermo Fisher Scientific Inc. (TMO) operates as a supreme, fortress-like core holding that perfectly synthesizes structural capital defense with exceptional upside business execution. Fundamentally, the enterprise commands an unbreakable economic monopoly within the global life sciences sector, generating a massive $19.73 in free cash flow per share alongside a pristine 15.06% net profit margin. This immense profitability fully funds aggressive AI integration and strategic acquisitions while maintaining a virtually bulletproof 9.49% dividend payout ratio. CEO Marc Casper's euphoric guidance projecting 2026 as an "outstanding year" provides undeniable fundamental validation from the highest echelons of corporate leadership, backed by a recent trailing-month average analyst price target of $725. From a critical momentum awareness perspective, TMO is currently trading at $654.80, placing its distance from the absolute 52-week high of $683.63 at a highly constructive 4.22%. This recent consolidation phase has successfully bled the extreme speculative froth out of the RSI, dropping it to a healthy 67.69. A stock trading this close to its 52-week highs on the back of fundamentally driven earnings beats, rather than speculative hype, demonstrates profound institutional conviction. This price action, combined with an exceptionally defensive beta of 0.854, drastically limits downside exposure while ensuring investors acquire a fundamentally dominant asset during a necessary algorithm
What this score has been worth
ClaritX scores TMO 87 out of 100 (snapshot 2026-10-05).
Every ClaritX analysis is scored first and judged only on what the stock did afterwards. Across the 203 analyses that scored in the 85-89 band, the average forward return was +1.7% with a 52% win rate, -3.7pp against the S&P 500. That is a measured tendency across many names, not a forecast for TMO — roughly 48% of stocks in this band still lost money.
The full band-by-band table, including the bands that lost, is on the AI Rank Report; the live strategy arms behind it are on the AI Track Record, losses published.